Abstract
P-111 PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have